Thus IPF-specific molecular biomarkers would facilitate classification of patient subgroups most likely to benefit from therapies like PI3K inhibitors, Akt degraders or senolytic cocktails. The gene discussed is AKT1; the disease is idiopathic pulmonary fibrosis.